Advisors Maxx Chatsko

FILTER CONTENT

Research

By Maxx ChatskoPublished On: May 12, 2022
NeuBase Therapeutics Tries to Thread a Needle
READ MORE
By Maxx ChatskoPublished On: May 12, 2022
Avita Medical Hums Along, Awaiting Data Readouts
READ MORE
By Maxx ChatskoPublished On: April 21, 2022
The Colon Cancer Screening Gauntlet Has Been Thrown
READ MORE
By Maxx ChatskoPublished On: March 7, 2022
Toripalimab is Not the Biggest Source of Uncertainty for Coherus BioSciences
READ MORE
By Maxx ChatskoPublished On: February 8, 2022
Will Solid-State Batteries Live Up to the Hype?
READ MORE
By Maxx ChatskoPublished On: January 26, 2022
“Very High Risk” Isn’t Very Helpful
READ MORE
By Maxx ChatskoPublished On: January 19, 2022
Coherus BioSciences: Circle Your Calendars for February 10
READ MORE
By Maxx ChatskoPublished On: January 14, 2022
Should You Invest in Synthetic Biology Stocks?
READ MORE
By Maxx ChatskoPublished On: January 7, 2022
Avita Medical is Way Ahead of (My) Schedule
READ MORE
By Maxx ChatskoPublished On: January 6, 2022
Cystic Fibrosis Foundation Invests Up to $5 Million in BiomX
READ MORE
By Simon EricksonPublished On: December 28, 2021
Buy Dicerna Pharmaceuticals (from October 2021)
READ MORE
By Maxx ChatskoPublished On: December 26, 2021
NeuBase Therapeutics Lays Foundation for Partnerships
READ MORE
By Samantha BaileyPublished On: December 20, 2021
Can Better Antibodies Disrupt Cell Therapy?
READ MORE
By Maxx ChatskoPublished On: December 15, 2021
We’re Closing Our Dicerna Pharmaceuticals Position
READ MORE
By Maxx ChatskoPublished On: November 23, 2021
Sell Nano-X Imaging
READ MORE
By Maxx ChatskoPublished On: November 23, 2021
Sell MP Materials
READ MORE